Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

(2017) Myriam Delaunay et al.   EUROPEAN RESPIRATORY JOURNAL

Challenges faced when identifying patients for combination immunotherapy

(2017) Marc S Ernstoff et al.   Future Oncology

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis

(2017) Anna J. Lomax et al.   International Journal of Rheumatic Diseases

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

(2017) Jarushka Naidoo et al.   ONCOLOGIST

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

(2017) Animesh Jain et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis

(2017) Jiaying Wu et al.   Scientific Reports

Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer

(2017) Noelia Rivera et al.   JAMA Dermatology

Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer

(2017) Maria E. Suarez-Almazor et al.   Arthritis & Rheumatology

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

(2017) Eileen Shiuan et al.   Journal for ImmunoTherapy of Cancer

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

(2017) Julia Escandon et al.   Journal for ImmunoTherapy of Cancer

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

(2017) Benjamin L. Maughan et al.   Frontiers in Oncology

Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes

(2016) James J. Chamberlain et al.   ANNALS OF INTERNAL MEDICINE

Managing Adverse Events With Immune Checkpoint Agents

(2016) Ramona Dadu et al.   CANCER JOURNAL

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Neurologic complications of immune checkpoint inhibitors

(2016) Andreas F. Hottinger   CURRENT OPINION IN NEUROLOGY

Programmed cell death-1 pathway inhibitors in genitourinary malignancies

(2016) Abhishek Tripathi et al.   CURRENT OPINION IN UROLOGY

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’

(2016) Raul S Gonzalez et al.   HISTOPATHOLOGY

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

(2016) L. Marthey et al.   Journal of Crohns & Colitis

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

(2016) Frank B. Cortazar et al.   KIDNEY INTERNATIONAL

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

(2016) Jeffrey S. Weber et al.   ONCOLOGIST

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

(2016) Lucie Heinzerling et al.   Journal for ImmunoTherapy of Cancer

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis

(2016) Zhijuan Lin et al.   PLoS One

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ipilimumab-associated Hepatitis

(2015) Melanie Johncilla et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Ipilimumab Granulomatous Interstitial Nephritis

(2015) Bijin Thajudeen et al.   AMERICAN JOURNAL OF THERAPEUTICS

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Safety of Infusing Ipilimumab Over 30 Minutes

(2015) Parisa Momtaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicities of Immunotherapy for the Practitioner

(2015) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

(2015) Alexander Faje   Pituitary

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

(2015) Jason J. Luke et al.   Oncotarget

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

(2015) Douglas B. Johnson et al.   Cancer Immunology Research

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

(2014) G. T. Gibney et al.   CLINICAL CANCER RESEARCH

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

(2014) Mabel Ryder et al.   ENDOCRINE-RELATED CANCER

Kidney injuries related to ipilimumab

(2014) Hassane Izzedine et al.   INVESTIGATIONAL NEW DRUGS

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab

(2014) Rikke Andersen et al.   OncoImmunology

Ipilimumab-Associated Colitis: CT Findings

(2013) Kyung Won Kim et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

(2013) Kyung Won Kim et al.   INVESTIGATIONAL NEW DRUGS

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

(2013) Salvatore Maria Corsello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab-induced acute severe colitis treated by infliximab

(2013) Cecile Pagès et al.   MELANOMA RESEARCH

Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review

(2013) Maurizio Pompili   WORLD JOURNAL OF GASTROENTEROLOGY

The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease

(2012) Ming Valerie Lin et al.   DIGESTIVE DISEASES AND SCIENCES

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected Myocarditis

(2012) Philipp Lurz et al.   JACC-Cardiovascular Imaging

Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission

(2011) Wouter V. Vogel et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

α-CTLA-4 mAb-associated Panenteritis

(2009) Darryl A. Oble et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Anti-CTLA4 Antibody–Induced Lupus Nephritis

(2009) Fouad Fadel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems

(2008) B. R.J. H. Bird et al.   CLINICAL CANCER RESEARCH